Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Parameswaran Hari

Hematology & Oncology Milwaukee, WI Medical Doctor

NPI 1083665814 CMS profile 230528

9200 W Wisconsin Ave, Hematology And Oncology, Milwaukee, WI 53226

Open in the dashboard

General payments

$1,285,898

282 records reported · program years 2019–2025

Research payments

$515,713

Paid to them · 68 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,464,136 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Parameswaran Hari of Milwaukee, WI is reported in the CMS Open Payments database as having received $1,285,898 across 282 general payments and $515,713 in research payments paid to them. Separately, studies naming them as principal investigator received $4,464,136 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $329,300 22
2025 Research $2,255 3
2024 General $470,338 21
2024 Research $8,360 3
2023 General $141,517 11
2023 Research $110,950 9
2022 General $875 1
2022 Research $47,725 6
2021 General $85,781 54
2021 Research $4,060 12
2020 General $136,812 68
2020 Research $151,676 17
2019 General $121,276 105
2019 Research $190,688 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Parameswaran Hari
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Parameswaran Hari were reported at $329,300. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Parameswaran Hari Hematology & Oncology median Middle half National median
2019 $121,276 $529 $121–$2,516 $163
2020 $136,812 $339 $82–$2,213 $114
2021 $85,781 $263 $49–$1,965 $132
2022 $875 $416 $103–$2,395 $149
2023 $141,517 $542 $125–$2,646 $160
2024 $470,338 $692 $141–$3,008 $164
2025 $329,300 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $796,238 46 payments
  2. GlaxoSmithKline, LLC. $210,063 26 payments
  3. Celgene Corporation $99,702 76 payments
  4. Karyopharm Therapeutics Inc. $36,737 14 payments
  5. Janssen Biotech, Inc. $26,753 26 payments
  6. Sanofi-Aventis U.S. LLC $19,925 4 payments
  7. Genzyme Corporation $19,592 15 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $19,289 8 payments
  9. Incyte Corporation $16,281 13 payments
  10. Amgen Inc. $11,280 19 payments
  11. Other $30,040 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,145,347 123 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $87,151 29 payments
  3. Honoraria $30,219 11 payments
  4. Travel and Lodging $17,915 52 payments
  5. Food and Beverage $5,266 67 payments
Products named General payments · program years 2019–2025
  1. ELREXFIO $787,738 42 payments
  2. Revlimid Hematology $51,059 30 payments
  3. XPOVIO $36,737 14 payments
  4. Revlimid Hematology / Oncology $27,539 22 payments
  5. DARZALEX $22,966 22 payments
  6. NINLARO $17,089 7 payments
  7. Pomalyst $14,430 7 payments
  8. clonoSEQ $10,901 13 payments
  9. CD38 $9,263 8 payments
  10. Kyprolis $9,134 16 payments
  11. Other $29,252 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $281,400 25 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $173,777 14 payments
  3. Janssen Research & Development, LLC $59,020 23 payments
  4. Genzyme Corporation $1,181 4 payments
  5. Regeneron Pharmaceuticals, Inc. $335 2 payments

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record